Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Surmodics (SRDX)
NASDAQ:SRDX
Holding SRDX?
Track your performance easily
SRDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.17 - $42.44
Previous Close$37.59
Volume366.94K
Average Volume (3M)312.04K
Market Cap
$536.30M
Enterprise Value$527.64M
Total Cash (Recent Filing)$38.17M
Total Debt (Recent Filing)$29.52M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 06, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding14,267,000
10 Day Avg. Volume234,475
30 Day Avg. Volume312,044
Standard Deviation0.16
R-Squared0.16
Alpha-0.00766
Financial Highlights & Ratios
Price to Book (P/B)4.54
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)-66.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit8.65
Enterprise Value/Ebitda88.35
Forecast
1Y Price Target
$43.00Price Target Upside14.39% Upside
Rating ConsensusHold
Number of Analyst Covering3
SurModics News
PremiumCompany Announcements
Surmodics Inc. Reports Q4 and FY 2024 Results
PremiumCompany Announcements
Ronald B. Kalich Resigns from SurModics Board Amicably
Bulls Say, Bears Say
Bulls Say
Cash Flow ManagementCash flow from operations was better than anticipated, with a figure of -$2.0 million compared to the estimated -$3.4 million, indicating effective cash flow management.
Financial PerformanceSurmodics' revenue, adjusted EBITDA, and earnings per share have surpassed analyst expectations, highlighting strong financial performance.
Revenue GenerationThe company achieved $10.5 million in royalty and licensing revenue, significantly beating the projected $9.4 million, showcasing robust revenue generation.
Bears Say
Lack Of Financial GuidanceManagement chose to forego a conference call and suspended its previously issued financial guidance for FY/24.
Regulatory UncertaintySurmodics disclosed that it and GTCR had each received a request for additional information and documentary materials from the United States Federal Trade Commission in connection with the merger.
Revenue SlowdownSRDX's revenue growth, excluding the ABT milestone payment, slowed to 9% in F3Q24 from 18% in F2Q24.
---
Ownership Overview
4.35% Insiders
18.33% Mutual Funds
0.98% Other Institutional Investors
63.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRDX FAQ
What was Surmodics’s price range in the past 12 months?
Surmodics lowest stock price was $25.17 and its highest was $42.44 in the past 12 months.
What is Surmodics’s market cap?
Currently, no data Available
When is Surmodics’s upcoming earnings report date?
Surmodics’s upcoming earnings report date is Nov 06, 2024 which is 4 days ago.
How were Surmodics’s earnings last quarter?
Surmodics released its earnings results on Jul 31, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.338 by $0.068.
Is Surmodics overvalued?
According to Wall Street analysts Surmodics’s price is currently Undervalued.
Does Surmodics pay dividends?
Surmodics does not currently pay dividends.
What is Surmodics’s EPS estimate?
Surmodics’s EPS estimate is -$0.29.
How many shares outstanding does Surmodics have?
Surmodics has 14,267,000 shares outstanding.
What happened to Surmodics’s price movement after its last earnings report?
Surmodics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.338. Following the earnings report the stock price went down -0.241%.
Which hedge fund is a major shareholder of Surmodics?
Among the largest hedge funds holding Surmodics’s share is Gamco Investors, Inc. ET AL. It holds Surmodics’s shares valued at 7M.
---
SurModics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (14.39% Upside)
$43.00 (14.39% Upside)
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.88%
12-Months-Change
Fundamentals
Return on Equity
-1.21%
Trailing 12-Months
Asset Growth
-6.08%
Trailing 12-Months
Company Description
Surmodics
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
---
SRDX Earnings Call
Q2 2024
0:00 / 0:00
---
SRDX Stock 12 Month Forecast
Average Price Target
$43.00
▲(14.39% Upside)
Technical Analysis
---